Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5237-5242

  Unal, Dilek ^a   Eroglu, Celalettin ^a   Kurtul, Neslihan ^a   Oguz, Arzu ^a   Tasdemir, Arzu ^b  

^a Kayseri Education and Research Hospital ^*  (Turkey)

^b ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Neutrophil to lymphocyte ratio; Non small cell lung cancer; Platelet to lymphocyte ratio; Prognosis

Indexed keywords

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; LYMPHOCYTE; MALE; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE;

ADENOCARCINOMA; ADULT; AGED; BLOOD PLATELETS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; SURVIVAL RATE;

EID: 84887803609     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5237     Document Type: Article

References (25)

1. Asher V, Lee J, Innamaa A, Bali A (2011). Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol, 13, 499-503.
2. Assoian RK, Sporn MB (1986). Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol, 102, 1217-23.
3. Cedrés S, Torrejon D, Martínez A, et al (2012). Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol, 14, 864-9.
4. Chua W, Charles KA, Baracos VE, Clarke SJ (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer, 104, 1288-95.
5. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.
6. Divella R, Daniele A, Savino E, et al (2013). Circulating levels of transforming growth factor-β (TGF-β) and chemokine (C-X-C Motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer. Anticancer Res, 33, 1491-7.
7. Donskov F (2013). Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol, 23, 200-7.
8. Dubernard V, Arbeille BB, Lemesle MB, Legrand C (1997). Evidence for an alpha-granular pool of the cytoskeletal protein alpha-actinin in human platelets that redistributes with the adhesive glycoprotein thrombospondin-1 during the exocytotic process. Arterioscler Thromb Vasc Biol, 17, 2293-305.
9. Kaplan KL, Broekman MJ, Chernoff A, Lesznik GR, Drillings M (1979). Platelet alpha-granule proteins: studies on release and subcellular localization. Blood, 53, 604-18.
10. Kaya MG, Akpek M, Lam YY, et al (2013). Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: A prospective, multicenter study. Int J Cardiol, 15, 1557-4.
11. Kobayashi N, Usui S, Kikuchi S, et al (2012). Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer, 75, 223-7.
12. Kocyigit I, Eroglu E, Unal A, et al (2013). Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. J Nephrol, 26, 358-65.
13. Majeti BK, Lee JH, Simmons BH, Shojaei F (2013). VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer, 13, 213.
14. Négrier S, Escudier B, Gomez F, et al (2002). Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol, 13, 1460-8.
15. Paesmans M, Sculier JP, Libert P, et al (1995). Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol, 13, 1221-30.
16. Qian X, Tuszynski GP (1996). Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med, 212, 199-207.
17. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T (2012). Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol, 23, 265-73.
18. Schmidt H, Bastholt L, Geertsen P, et al (2005). Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer, 93, 273-8.
19. Stone RL, Nick AM, McNeish IA, et al (2012). Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med, 366, 610-8.
20. Teramukai S, Kitano T, Kishida Y, et al (2009). Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer, 45, 1950-8.
21. Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T (2012). Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res, 32, 3535-8.
22. Wang D, Yang JX, Cao DY, et al (2013). Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther, 6, 211-6.
23. Wang S, Zhang Z, Fang F, et al (2011). The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett, 2, 735-40.
24. Yao Y, Yuan D, Liu H, Gu X, Song Y (2013). Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother, 62, 471-9.
25. Zhang J, Huang SH, Li H, et al (2013). Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer. Med Oncol, 30, 352.